Research programme: small molecule lipid mediators - Resolvyx Pharmaceuticals

Drug Profile

Research programme: small molecule lipid mediators - Resolvyx Pharmaceuticals

Alternative Names: NPD 1; Resolvin D1; RvD 1; RX-05 - Resolvyx; RX-10005; RX-10008; RX-10065; RX-20001; RX-65

Latest Information Update: 04 May 2016

Price : $50

At a glance

  • Originator Resolvyx Pharmaceuticals
  • Class Omega 3 fatty acids; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Dry eyes; Inflammation

Most Recent Events

  • 04 May 2016 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 04 May 2016 Discontinued - Preclinical for Dry eyes in USA (Topical)
  • 04 May 2016 Discontinued - Preclinical for Age-related macular degeneration in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top